{"denoms":[{"counts":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"44"},{"groupId":"BG002","value":"25"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"7"},{"groupId":"BG005","value":"28"},{"groupId":"BG006","value":"17"},{"groupId":"BG007","value":"14"},{"groupId":"BG008","value":"5"},{"groupId":"BG009","value":"23"},{"groupId":"BG010","value":"8"},{"groupId":"BG011","value":"185"}],"units":"Participants"}],"groups":[{"description":"Participants in Cohort 1 were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 20 mg/kg Q2W on Days 1 and 15, plus budigalimab at a dose of 500 mg (Q4W) on Day 1 plus mFOLFOX6 over 48 hours (Q2W) on Day 1 and 15 of each 28-day cycle.","id":"BG000","title":"Cohort 1 - Safety Lead-in (TTX-030 + Budigalimab + mFOLFOX6)"},{"description":"Participants in Cohort 3B were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 20 mg/kg Q2W on Days 1 and 15, plus budigalimab at a dose of 500 mg (Q4W) on Day 1 plus mFOLFOX6 over 48 hours (Q2W) on Day 1 and 15 of each 28-day cycle.","id":"BG001","title":"Cohort 3B - Gastric (TTX-030 + Budigalimab + mFOLFOX6)"},{"description":"Participants in Cohort 12 were administered IV budigalimab at a dose of 500 mg (Q4W) on Day 1 plus mFOLFOX6 over 48 hours (Q2W) on Day 1 and 15 of each 28-day cycle.","id":"BG002","title":"Cohort 12 - Gastric (Budigalimab + mFOLFOX6"},{"description":"Participants in Cohort 3A were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 20 mg/kg Q2W on Days 1 and 15 plus mFOLFOX6 over 48 hours (Q2W) on Day 1 and 15 of each 28-day cycle.","id":"BG003","title":"Cohort 3A - Gastric (TTX-030 + mFOLFOX6)"},{"description":"Participants in Safety Lead-in Cohort 2 were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 30 mg/kg Q3W plus budigalimab 375 mg Q3W plus docetaxel at a dose of 75 mg/m2 Q3W on Day 1 of each 21-day treatment cycle.","id":"BG004","title":"Cohort 2 - mCRPC (TTX-030 + Budigalimab + Docetaxel)"},{"description":"Participants in Cohort 9 were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 20 mg/kg Q2W on Days 1 and 15 plus budigalimab at a dose of 500 mg (Q4W) on Day 1 plus gemcitabine 1000 mg/m2 + nab-paclitaxel 125 mg/m2 on Days 1, 8, and 15 each 28-day cycle.","id":"BG005","title":"Cohort 9 - Pancreatic (TTX-030 + Budigalimab + Gemcitabine + Nab-Paclitaxel)"},{"description":"Participants in Cohort 11 were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 20 mg/kg Q2W on Days 1 and 15 plus gemcitabine 1000 mg/m2 + nab-paclitaxel 125 mg/m2 on Days 1, 8, and 15 each 28-day cycle.","id":"BG006","title":"Cohort 11 - Pancreatic (TTX-030 + Gemcitabine + Nab-Paclitaxel)"},{"description":"Participants in Cohort 4 were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 30 mg/kg Q3W plus budigalimab at a dose of 375 mg Q3W on Day 1 of each 21-day treatment cycle.","id":"BG007","title":"Cohort 4 - CRC (TTX-030 + Budigalimab)"},{"description":"Participants in Cohort 6 were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 30 mg/kg Q3W plus budigalimab at a dose of 375 mg Q3W on Day 1 of each 21-day treatment cycle.","id":"BG008","title":"Cohort 6 - HNSCC (TTX-030 + Budigalimab)"},{"description":"Participants in Cohort 8 were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 30 mg/kg Q3W plus budigalimab at a dose of 375 mg Q3W on Day 1 of each 21-day treatment cycle.","id":"BG009","title":"Cohort 8 - GEC (TTX-030 + Budigalimab)"},{"description":"Participants in Cohort 10 were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 30 mg/kg Q3W plus pembrolizumab at a dose of 200 mg Q3W on Day 1 of each 21-day treatment cycle.","id":"BG010","title":"Cohort 10 - UCC (TTX-030 + Pembrolizumab)"},{"description":"Total of all reporting groups","id":"BG011","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"31"},{"groupId":"BG002","value":"14"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"12"},{"groupId":"BG006","value":"6"},{"groupId":"BG007","value":"9"},{"groupId":"BG008","value":"3"},{"groupId":"BG009","value":"12"},{"groupId":"BG010","value":"3"},{"groupId":"BG011","value":"102"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"11"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"16"},{"groupId":"BG006","value":"11"},{"groupId":"BG007","value":"5"},{"groupId":"BG008","value":"2"},{"groupId":"BG009","value":"11"},{"groupId":"BG010","value":"5"},{"groupId":"BG011","value":"83"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"9.40","value":"65.9"},{"groupId":"BG001","spread":"12.51","value":"59.5"},{"groupId":"BG002","spread":"8.70","value":"63.2"},{"groupId":"BG003","spread":"6.28","value":"62.5"},{"groupId":"BG004","spread":"7.95","value":"65.7"},{"groupId":"BG005","spread":"6.83","value":"65.7"},{"groupId":"BG006","spread":"9.5","value":"68.2"},{"groupId":"BG007","spread":"10.57","value":"61.4"},{"groupId":"BG008","spread":"6.57","value":"65.2"},{"groupId":"BG009","spread":"15.54","value":"61"},{"groupId":"BG010","spread":"7.42","value":"66.4"},{"groupId":"BG011","spread":"10.77","value":"63.1"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"13"},{"groupId":"BG006","value":"6"},{"groupId":"BG007","value":"5"},{"groupId":"BG008","value":"1"},{"groupId":"BG009","value":"8"},{"groupId":"BG010","value":"1"},{"groupId":"BG011","value":"57"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"26"},{"groupId":"BG002","value":"24"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"7"},{"groupId":"BG005","value":"15"},{"groupId":"BG006","value":"11"},{"groupId":"BG007","value":"9"},{"groupId":"BG008","value":"4"},{"groupId":"BG009","value":"15"},{"groupId":"BG010","value":"7"},{"groupId":"BG011","value":"128"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"22"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"9"},{"groupId":"BG006","value":"2"},{"groupId":"BG007","value":"2"},{"groupId":"BG008","value":"1"},{"groupId":"BG009","value":"3"},{"groupId":"BG010","value":"3"},{"groupId":"BG011","value":"69"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"2"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"1"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"9"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"6"},{"groupId":"BG005","value":"16"},{"groupId":"BG006","value":"12"},{"groupId":"BG007","value":"10"},{"groupId":"BG008","value":"3"},{"groupId":"BG009","value":"17"},{"groupId":"BG010","value":"5"},{"groupId":"BG011","value":"99"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"2"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"1"},{"groupId":"BG009","value":"2"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"8"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"21"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"8"},{"groupId":"BG006","value":"2"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"1"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"3"},{"groupId":"BG011","value":"61"}]}],"title":"South Korea"},{"categories":[{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"7"},{"groupId":"BG005","value":"20"},{"groupId":"BG006","value":"15"},{"groupId":"BG007","value":"14"},{"groupId":"BG008","value":"4"},{"groupId":"BG009","value":"23"},{"groupId":"BG010","value":"5"},{"groupId":"BG011","value":"124"}]}],"title":"United States"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Region of Enrollment","unitOfMeasure":"Participants"}]}